CareDx, Inc (NASDAQ:CDNA - Get Free Report)'s share price passed above its fifty day moving average during trading on Monday following insider buying activity. The stock has a fifty day moving average of $17.54 and traded as high as $19.23. CareDx shares last traded at $19.07, with a volume of 777,225 shares trading hands.
Analyst Ratings Changes
Several research analysts recently issued reports on the stock. Stephens reiterated an "overweight" rating and issued a $40.00 price target on shares of CareDx in a research note on Monday, May 5th. The Goldman Sachs Group decreased their target price on shares of CareDx from $34.00 to $26.00 and set a "buy" rating for the company in a research note on Thursday, April 17th. HC Wainwright reaffirmed a "neutral" rating and set a $25.00 price objective on shares of CareDx in a research report on Monday, May 5th. Finally, Wall Street Zen lowered CareDx from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, CareDx currently has a consensus rating of "Moderate Buy" and an average target price of $30.33.
View Our Latest Report on CDNA
CareDx Price Performance
The company has a market cap of $1.06 billion, a P/E ratio of -7.06 and a beta of 2.18. The company's 50-day moving average is $17.54 and its two-hundred day moving average is $20.17.
CareDx (NASDAQ:CDNA - Get Free Report) last posted its earnings results on Wednesday, April 30th. The company reported $0.09 EPS for the quarter, topping analysts' consensus estimates of $0.06 by $0.03. The business had revenue of $84.69 million during the quarter, compared to analyst estimates of $84.56 million. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The company's quarterly revenue was up 17.6% compared to the same quarter last year. During the same quarter last year, the company earned ($0.03) EPS. Equities research analysts anticipate that CareDx, Inc will post -0.9 EPS for the current year.
Institutional Investors Weigh In On CareDx
Several large investors have recently bought and sold shares of CDNA. Swiss National Bank grew its stake in shares of CareDx by 1.9% in the fourth quarter. Swiss National Bank now owns 98,600 shares of the company's stock worth $2,111,000 after acquiring an additional 1,800 shares during the period. Allspring Global Investments Holdings LLC grew its position in CareDx by 59.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 327,343 shares of the company's stock worth $7,008,000 after purchasing an additional 122,356 shares during the period. KLP Kapitalforvaltning AS bought a new stake in CareDx in the 4th quarter worth approximately $208,000. Nuveen Asset Management LLC grew its position in CareDx by 15.5% in the 4th quarter. Nuveen Asset Management LLC now owns 448,113 shares of the company's stock worth $9,594,000 after purchasing an additional 60,050 shares during the period. Finally, Principal Financial Group Inc. grew its position in CareDx by 6.5% in the 4th quarter. Principal Financial Group Inc. now owns 18,984 shares of the company's stock worth $406,000 after purchasing an additional 1,151 shares during the period.
CareDx Company Profile
(
Get Free Report)
CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider CareDx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CareDx wasn't on the list.
While CareDx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
